small-molecule

And they might be more lucrative than generic versions of small-molecule drugs, if the complexity of developing these larger molecules limits competition.

FDA Sets Path for Biotech Drug Copies Thomas M. Burton 2012

Biosimilars are intended to be close copies of biologics, which are large-molecule drugs derived from living cells, as opposed to traditional chemical-based, small-molecule drugs.

Merck Teams Up With Parexel on Biosimilars Peter Loftus 2011

Although OSI is painting itself as a biotech company, Tarceva and its entire pipeline are actually small-molecule drugs, which are chemical compounds more commonly developed by the traditional large pharmaceutical companies.

OSI Rejects Astellas Bid Thomas Gryta 2010

Although OSI is painting itself as a biotech company, Tarceva and its entire pipeline are actually small-molecule drugs, which are chemical compounds more commonly developed by the traditional large pharmaceutical companies.

OSI Rejects Astellas Bid Thomas Gryta 2010

Co. Generics for small-molecule drugs, such as Sanofi-Aventis's Ambien insomnia drug, don't require such additional testing.

Merck Move Shows Hurdles to Developing Biotech Generics 2010

Although OSI is painting itself as a biotech company, Tarceva and its entire pipeline are actually small-molecule drugs, which are chemical compounds more commonly developed by the traditional large pharmaceutical companies.

OSI Rejects Astellas Bid Thomas Gryta 2010

With respect to cells we are certainly in the tinkering stage, but even small-molecule drug chemistry, which has 100 years of science behind it, is still more a matter of making small modifications to known compounds, many of which are natural products, rather than purely rational design.

Blurring the Line 2007

With respect to cells we are certainly in the tinkering stage, but even small-molecule drug chemistry, which has 100 years of science behind it, is still more a matter of making small modifications to known compounds, many of which are natural products, rather than purely rational design.

Blurring the Line 2007

Teva Pharmaceutical Industries Ltd. Chief Executive Shlomo Yanai last week estimated that producing a generic small-molecule drug costs about $5 million to $10 million, while developing a generic biologic will likely cost $100 million to $150 million.

Generic Biologics Face Hurdles 2009

There are only generic versions of traditional, small-molecule drugs.

Rep. Anna Eshoo: Setting the Record Straight on Our Health Care Legislation 2009